In a decisive public health intervention, the Tamil Nadu government has banned the sale and distribution of Coldrif cough syrup across the state after reports linked the medicine to the deaths of several children in Madhya Pradesh and Rajasthan. The move comes amid growing concerns over pharmaceutical safety and regulatory oversight.
The ban was announced by the Tamil Nadu Department of Drugs Control Administration (DDCA) after initial investigations suggested that Coldrif syrup contained diethylene glycol (DEG), a toxic industrial chemical. DEG, which is not approved for use in pharmaceutical formulations, is known to cause severe kidney damage and has been linked to fatal poisoning incidents worldwide.
The deaths first came to light in late September when hospitals in Madhya Pradesh reported a cluster of unexplained fatalities among children treated for cough and cold. Subsequently, a similar pattern was reported in Rajasthan. Preliminary laboratory tests pointed to the presence of harmful chemicals in Coldrif syrup, prompting urgent health advisories and investigations.
According to DDCA officials, the ban on Coldrif syrup is an immediate step to prevent further harm. All stock of the product has been seized and distribution halted. Drug inspectors have been directed to ensure compliance across pharmacies, wholesalers, and distributors in Tamil Nadu.
“Public safety is our top priority,” said a DDCA spokesperson. “The presence of diethylene glycol in a medication meant for children is deeply alarming, and we are taking all necessary steps to ensure such incidents do not occur again.”
In parallel, the Drug Controller General of India (DCGI) has ordered an inspection of the manufacturing unit in Kancheepuram, Tamil Nadu, where Coldrif syrup is produced. The inspection will assess quality control measures and investigate how contamination occurred.
Health authorities in Madhya Pradesh and Rajasthan have sent syrup samples to the Virology Institute in Pune for further testing to confirm the preliminary findings. The Union Health Ministry has set up a multi-agency investigation team to examine the case, with a focus on manufacturing standards, supply chain integrity, and regulatory enforcement.
Impact and Public Concern
The deaths have heightened public anxiety over medicine safety, especially in paediatric care. Several consumer rights groups have demanded stricter laws for pharmaceutical manufacturing and improved oversight mechanisms to avoid such tragedies.
Experts say the incident highlights serious gaps in quality control and regulatory vigilance. “This is not just a regional issue but a nationwide concern,” said Dr. Meera Chandrasekar, a public health expert. “Stringent testing and periodic audits must be enforced to prevent toxic substances from entering the market.”
The Tamil Nadu ban aligns with similar actions taken by other states after Coldrif syrup-related fatalities were reported. Authorities have urged parents to avoid self-medicating children and to immediately report any unusual symptoms such as persistent vomiting, drowsiness, or reduced urine output after administering cough syrups.
Way Forward
The Coldrif cough syrup case underscores the urgent need for enhanced pharmaceutical oversight in India. As investigations continue, authorities are expected to announce stricter regulations, including random batch testing and a robust recall mechanism for harmful drugs.
For now, the Tamil Nadu government’s ban is a preventive step aimed at safeguarding public health and restoring trust in the healthcare system. Parents, doctors, and pharmacists across the state have been alerted to the ban, and public advisories have been issued through official channels.
